Colombia moves to 'unilaterally' set price for Novartis' Gleevec - FiercePharma
FiercePharmaColombia moves to 'unilaterally' set price for Novartis' GleevecFiercePharmaDespite behind-the-scenes pressure to call off its plans to usher in cheap generics of Novartis' ($NVS) cancer drug Gleevec, Colombia says it's ready to take the next step in its pricing fight.
Colombia To Lower Price Of Novartis Cancer Drug Gleevec - Law360 (subscription)
Colombia To Lower Price Of Novartis Cancer Drug GleevecLaw360 (subscription)While Novartis would continue to have the exclusive rights to commercialize Gleevec, the Swiss pharmaceutical would have to sell it at a price set by the National Commission of Medical Prices and confirmed by a presidential delegate and by the nation's .
Colombia plans to unilaterally lower the cost of a Novartis cancer drug - STAT
STATColombia plans to unilaterally lower the cost of a Novartis cancer drugSTATIn a dramatic move, the Colombian health minister plans to unilaterally force Novartis to lower the price for its Gleevec cancer medicine after more than two weeks of talks over a price cut went nowhere, according to reports and sources in Colombia.
Group of rare blood cancers respond to new treatment pioneered by Stanford physician - Stanford Medical Center Report
Stanford Medical Center ReportGroup of rare blood cancers respond to new treatment pioneered by Stanford physicianStanford Medical Center ReportHowever, the only currently approved treatment for advanced SM, a kinase inhibitor marketed by Novartis as imatinib, or Gleevec, is not active against the KIT protein with the D816V mutation — leaving most patients without an effective treatment.
Novartis, Colombia face off over cancer drug cost - STAT
STATNovartis, Colombia face off over cancer drug costSTATFor the past several weeks, Colombian Health Minister Alejandro Gaviria has vowed to find a way to force Novartis to lower the price of its Gleevec leukemia treatment.